Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenPenta SD
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenPenta SD is an investigational pentavalent meningococcal vaccine formulation developed by Sanofi Pasteur. It is designed to provide protection against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. The "SD" designation refers to a specific formulation (likely "Standard Dose") being evaluated in clinical trials alongside other variants such as "fHD" (likely "full High Dose"). The vaccine aims to simplify the immunization schedule by combining protection against the five most common serogroups into a single product, potentially improving coverage and compliance in infants, toddlers, and children. It typically consists of capsular polysaccharide conjugates for serogroups A, C, W, and Y, combined with recombinant protein antigens for serogroup B.
- Other names
- MenABCWY vaccinepentavalent meningococcal vaccineMenPenta
02
Targets
Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on MenPenta SD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenPenta SD.